HK Stock Market Move | ZYLOXTB(02190) rose more than 5% midday, with several innovative products expected to be approved one after another. The company's profit potential is expected to continue to increase.

ZYLOXTB (02190) rose more than 5% during the trading day. As of the time of writing, it has risen by 3.76% to 23.2 Hong Kong dollars, with a trading volume of 15.39 million Hong Kong dollars. On the news front, earlier this month, ZYLOXTB's subsidiary, Guichuang Medical, received approval from the National Medical Products Administration for the ZYLOX KINGKONG Peripheral High-Pressure Balloon Catheter, which was independently developed. The product is suitable for use in percutaneous intravascular angioplasty in peripheral vessels including the upper limbs, kidneys, iliac and femoral arteries, as well as the treatment of stenosis in autologous or dialysis arteriovenous fistulas, and for post-expansion of stents and covered stents in the peripheral vascular system. China Securities Co., Ltd. previously stated that the company is a leading enterprise in the domestic and foreign peripheral intervention and neurointervention industry, with a rich product pipeline. Several innovative products are expected to receive approval one after another. Against the backdrop of some products benefiting from centralized procurement and accelerated import substitution, the company's endogenous business is expected to maintain rapid growth. The company achieved profitability for the first time in 2024, and with the continuous expansion of sales scale and the ongoing improvement of management and operational efficiency, the company's profitability is expected to continue to increase. The company has sufficient funds on hand, with cash on hand as of 25H1 reaching 2.53 billion yuan. It is expected that the company will continue to increase its investment in product research and development and academic promotion, and seek opportunities for external expansion through mergers and acquisitions and external cooperation, in order to continuously consolidate its position as an industry leader.